NEW YORK, NY--(Marketwired - Jan 25, 2016) - Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") issues this corrected notice to clarify the case caption in the securities class action lawsuit it filed on behalf of the St. Paul Teachers' Retirement Fund Association against HeartWare International, Inc. ("HeartWare" or the "Company") (
HeartWare is a medical device company that develops and manufactures miniaturized implantable heart pumps. The Complaint alleges that during the Class Period, HeartWare and certain of its senior executives violated provisions of the Exchange Act by making numerous false and misleading statements and omissions of material fact, including in press releases and in statements during conferences and conference calls with analysts and investors. Specifically, the Complaint alleges that after the U.S. Food and Drug Administration ("FDA") issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company's sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that they therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing.
The truth concerning the Company's failure to remediate the regulatory failures identified by the FDA and its impact on the viability of MVAD was revealed through a series of disclosures. On September 1, 2015, HeartWare announced a highly dilutive acquisition of Valtech Cardio, Ltd., a manufacturer of medical devices used to treat heart disease. The Complaint alleges that this disclosure revealed significant obstacles to the timely approval of MVAD. On September 9, 2015, HeartWare disclosed that it was halting enrollment in the MVAD trial because of a manufacturing problem with the device. On October 12, 2015, HeartWare disclosed that patients in the MVAD trial had suffered adverse events, and that the trial would be further delayed. And on January 11, 2016, the Company revealed that problems with MVAD had resulted in serious adverse events in nearly half of the patients so far implanted with the device, and that the trial would be delayed indefinitely. In response to each of these disclosures, the price of HeartWare's common stock declined significantly. In total, HeartWare's common stock fell 72% from its Class Period high to close at $26.50 per share on January 12, 2016.
This corrected notice does not alter the deadline for filing a motion to seek appointment as lead plaintiff in this action that was triggered by the notice published by BLB&G on January 22, 2016. If you wish to serve as lead plaintiff for the Class, you must file a motion with the Court no later than 60 days from January 22, 2016. Accordingly, the deadline for filing a motion for appointment as lead plaintiff is March 22, 2016. Any member of the proposed Class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed Class.
If you wish to discuss this Action or have any questions concerning this notice or your rights or interests, please contact Michael Blatchley of BLB&G at (212) 554-1281, or via e-mail at michaelb@blbglaw.com .
Since its founding in 1983, BLB&G has built an international reputation for excellence and integrity. Specializing in securities fraud, corporate governance, shareholders' rights, employment discrimination, and civil rights litigation, among other practice areas, BLB&G prosecutes class and private actions on behalf of institutional and individual clients worldwide. Unique among its peers, BLB&G has obtained several of the largest and most significant securities recoveries in history, recovering billions of dollars on behalf of defrauded investors. More information about BLB&G can be found online at www.blbglaw.com .
CONTACT: Michael Blatchley Bernstein Litowitz Berger & Grossmann LLP 1251 Avenue of Americas, 44 th Floor New York, New York 10020 Telephone: (212) 554-1281
